|
1.
|
Number 532
(Replaces No. 387, November 2007 and No. 322, November 2005)
ABSTRACT: Although improvement in long-term health is no longer an indication for menopausal hormone therapy, evidence supporting fewer adverse events in younger women, combined with its high overall...
|
August 2012
PDF Download
|
|
2.
|
Washington, DC -- Today K-V Pharmaceutical Company announced that it is reducing the cost of its drug Makena™ from $1,500 per dose to $690 per dose, clearly acknowledging the negative impact of...
|
April 2011
|